Przetwarzanie przeciwciał mAb

Monoclonal Antibodies (mAbs) are known as targeted therapies because they work by seeking out specific proteins on the surfaces of cells.

Successfully used to treat cancers, tumours and other serious diseases, the sector size for monoclonal antibodies is growing steadily, prompting more and more pharmaceutical companies to enter the market.

Monoclonal Antibodies

Compared with other biopharmaceutical products, monoclonal antibodies are large proteins that require relatively high administration doses and traditionally necessitate high-volume manufacturing equipment/systems and facilities. 

The GEA Advantage

GEA offers state-of-the-art stainless steel bioreactors for the production of mAbs. Support processes, such as media preparation and harvest systems are also available.

The cell culture process is done in several steps, starting with 10 L precultures and successively cultivating intermediate batches of, for example, 40, 200, 1000 and 5000 L, to the final production volume of up to 20,000 L. These systems comprise the vessel, with the stirrer as the core element, and peripherals such as temperature control systems, CIP components, aeration and deaeration systems, input systems and automated sensors, actuators and the operator interface.

The process integration of separators and filters for the harvest step is also within our scope of service. As fermentation is a long process, and because of the high sensitivity of the cells — and the need for operator and product safety — all system components are designed according to the latest standards and have the highest grade of finish quality.

Oncology Solutions

GEA can supply a specialized solution when no standard off-the-shelf one exists, particularly for toxic or highly potent drugs such as cytostatics or echo contrast media. With our innovative ideas and fresh approaches, together with your project team, we will find a solution that’s tailored to your needs — from basic engineering to fabrication and qualification.